- Active, not recruiting
NCT03915184: Phase 1 - Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory
Updated: Feb 10
(LUMMICAR STUDY 2)
NCT03915184: Phase 1 - Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2)
A phase 1b, open label, multi-center, Clinical Study of Chimeric Antigen Receptor T Cells targeting BCMA in patients with relapsed and or refractory multiple myeloma.
Sponsor
Multiple locations International study
ClinicalTrials.gov Identifier: NCT03915184
Open Label, Multi-center, Phase 1b/2 Clinical Trial to Evaluate the Safety and Efficacy of Autologous CAR BCMA T Cells (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2)
First Posted : April 16, 2019
Click here for details on Clinicaltrials.gov
Anti-BCMA-targeting CAR-T Cells (Code C176023)
Genetic: CAR-BCMA T cells
autologous anti-BCMA-CAR-4-1BB-CD3zeta-expressing T cells CT053
BCMA Car-T (CT053)
CAR-BCMA T cells CT053
Biological: CT053
Drug: Fludarabine
Drug: Cyclophosphamide
Related Study:
(LUMMICAR STUDY 1)
Poster #2821: Sustainable Efficacy and Safety Results from LUMMICAR STUDY 1: A Phase 1/2 Study of Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT053) in Chinese Subjects with Relapsed and/or Refractory Multiple Myeloma
Poster #1751: Integrated Analysis of B-cell Maturation Antigen-Specific CAR T Cells (CT053) in Relapsed and Refractory Multiple Myeloma Subjects by High-Risk Factors
704.Cellular Immunotherapies: Clinical| November 5, 2021
Integrated Analysis of B-Cell Maturation Antigen-Specific CAR T Cells (CT053) in Relapsed and Refractory Multiple Myeloma Subjects By High-Risk Factors
704.Cellular Immunotherapies: Clinical| November 5, 2021
Sustainable Efficacy and Safety Results from Lummicar Study 1: A Phase 1/2 Study of Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT053) in Chinese Subjects with Relapsed and/or Refractory Multiple Myeloma
133 Results from Lummicar-2: A Phase 1b/2 Study of Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT053) in Patients with Relapsed and/or Refractory Multiple Myeloma
Program: Oral and Poster Abstracts
Type: Oral
Session: 653. Myeloma/Amyloidosis: Therapy, excluding Transplantation: CAR T Therapies for Myeloma: Novel Approaches and Longer-Term Follow Up Data
Hematology Disease Topics & Pathways:
multiple myeloma, Biological, Diseases, Therapies, CAR-Ts, Plasma Cell Disorders, Lymphoid Malignancies, Clinically relevant
Saturday, December 5, 2020: 10:30 AM
- Florida: Moffitt Cancer Center Tampa
- Massachusetts: Dana-Farber Cancer Institute/Harvard Cancer Center Boston
- Minnesota: Mayo Clinic Rochester Minnesota
- Texas: The University of Texas MD Anderson Cancer Center Houston
- Texas: UT Southwestern Medical Center Dallas
- Wisconsin: Medical College Of Wisconsin Milwaukee
Locations
United States, Arizona
United States, California
United States, Colorado
United States, Florida
United States, Massachusetts
United States, Michigan
United States, Michigan
United States, New York
United States, Tennessee
United States, Texas
United States, Utah
United States, Wisconsin
Canada, Ontario